NLRP3 and metabolic dysfunction-associated steatohepatitis: To investigate whether Cas9/gNLRP3@M-N could also confer protection against chronic liver inflammation mediated by the NLRP3 inflammasome, we treated Gubra-Amylin NASH (GAN)-induced MASH mouse model with multiple intravenous injections of Cas9/gNLRP3@M-N following the treatment protocol shown in Figure 5A. Cas9/gNLRP3@M-N treatment significantly inhibited NLRP3 expression (Figure 5B).